Considering that an active enhancer requires combined enrichment for H3K27ac with H3K4me123, we identified 254 (out of 832) DAR with predicted regulatory activity over 201 DEG within the same TAD that are only present in myeloma and not normal PC (Fig. 2e and Supplementary Data 6), i.e., they are de novo formed (e.g., the enhancers predicted to regulate HGF and UCHL1 shown above). Here, UCHL1 is linked to plasma cell myeloma.